Pelacarsen's Phase 3 Failure Puts $2.3 Billion Lp(a) Bets at Risk

Ionis fell 28.1% after pelacarsen cut Lp(a) but not heart attacks or strokes, casting doubt on Amgen's olpasiran and Eli Lilly's lepodisiran.